Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

Click here to view

SSIEM 2022

Preliminary results of STAAR, a Phase I/II study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease and long-term follow-up
October 4th, 2022